Clovis Oncology, Inc.
C6O.DE
Deutsche Börse0.09
EUR
- -
- -
Clovis Oncology, Inc.
C6O.DE
(Deutsche Börse)
Recent
price
0.09
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Clovis Oncology, Inc. (C6O.DE), a biopharmaceutical company focused on acquiring, developing, and commercializing anti-cancer agents targeting specific cancer subsets through precision medicine approaches including companion diagnostics, operates primarily in the United States, Europe, and additional international markets; its main products and services historically encompass Rubraca (rucaparib), an oral PARP inhibitor approved for recurrent epithelial ovarian, fallopian tube, primary peritoneal cancer, and metastatic castration-resistant prostate cancer; rociletinib, a targeted therapy for non-small cell lung cancer; lucitanib, an investigational VEGFR/FGFR inhibitor for advanced solid tumors; and FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein; founded in 2009 and headquartered in Boulder, Colorado, the company underwent major strategic shifts in late 2022 through 2023, including a Chapter 11 bankruptcy filing in December 2022 followed by asset sales during liquidation proceedings, with Rubraca sold to Pharma& Schweiz GmbH for $70 million upfront plus milestones, FAP-2286 transferred to Novartis Innovative Therapies AG for $50 million upfront plus up to $630.75 million in milestones, and its plan of liquidation confirmed effective July 2023, resulting in cessation of operations as a going concern.